Charles Padua

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial

Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi et al. · Journal of Clinical Oncology · 2023 · 91 citations · Full text

Medicine, Oncology, Pharmacology +16

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from &gt;4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

Johann S. de Bono, Karim Fizazi, Fred Saad et al. · Annals of Oncology · 2019 · 49 citations

Medicine, Oncology, Urology +11

Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer

André M. Murad, Rodrigo C. Guimarães, Bruno C. Aragão et al. · American Journal of Clinical Oncology · 2003 · 32 citations

Medicine, Oncology, Pharmacotherapy +11

Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer

André M. Murad, Rodrigo C. Guimarães, Bruno C. Aragão et al. · American Journal of Clinical Oncology · 2003 · 24 citations

Medicine, Oncology, Pharmacotherapy +11

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel et al. · European Journal of Cancer · 2022 · 20 citations · Full text

Pharmacy, Oncology, Pharmacology +17